{"title": "PDF", "author": "PDF", "url": "https://www.cs.unm.edu/~forrest/publications/variable-efficacy.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "8200 1,000 500 (c)v2only 1200 1,000 500 (d)v1andv2 31 200 1,000 1,000 A/England/42/72 1.2 (0.73 1.0 1974(H3N2) A/HongK ong/1/68X A/England/42/72 A/PortChalmers/1/73 0.40 1976(H3N2) A/PortChalmers/1/73 A/PortChalmers/1/73 A/Victoria/3/75 A/Phillippines/2/82 1.00 1.18 1985(B) B/USSR/100/83 B/USSR/100/83 B/AnnArbor/1/86 0.6 0.6 0.87 1.02 1986(H1N1) A/Chile/1/83 A/Chile/1/83 A/Taiwan/1/86 2.0 *0.0 2.0 1987(B) B/AnnArbor/1/86 0.38 1987(H3N2) A/Mississippi/1/85 A/Leningrad/360/86 A/Sichuan/2/87 3.3 strains,antigenic vaccinees - OutbreakHoskins study Keitel studyObserved Predicted Figure1: 21(a)Vaccine1B cells Ball of Stimulation Memory cells and antibodies produced in response to vaccine1 (b)Vaccine2Cells and antibodies in the intersection crossreact with both antigens Preexisting crossreactive 02505007501000125015001750200022502500Weighted antibody levels Viral load(a) Negative interference Ab reactive with vaccine 1 Ab reactive with vaccine 2 Ab reactive with epidemic virus Viral load Vaccination 2 . Vaccination 1 .Epidemic challenge 050100150200 02505007501000 (b) Vaccine2 only control 050100150200 0 3 6 9 12 15 18 21 2402505007501000 Time (months)(c) Positive interference Figure3: 230.00.20.40.60.81.0Attack rate /(a)Prior season Current season Both seasons 0.00.20.40.60.81.01.2 0.0 0.5 1.0 1.5 2.0 2.5 3.0Vaccine efficacy in repeat vaccinees 0 relative to efficacy in first-time vaccinees 0 Vaccine to epidemic strain antigenic distance(b)Observed 240.00.20.40.60.81.01.21.4 0.00.20.40.60.81.01.21.4Observed ratio 1 Predicted ratioHoskins outbreaks Keitel outbreaks Linear regression Figure5: 25 "}